One Day Programme: Drafting and Negotiating Clinical Trial Agreements (London, United Kingdom - November 5, 2019) -

DUBLIN--()--The "Drafting and Negotiating Clinical Trial Agreements" conference has been added to's offering.

Clinical trial agreements are one of the most important agreements in the pharma industry as no research can start without the right agreement in place between sponsor and host organisation. They provide a contract that manages the relationship and responsibilities of both parties and provide for the allocation of risk, obligations, the protection of academia, terms of collaboration, IP rights and much more.

This intensive one-day programme, delivered by experts in the field, will provide you with a full understanding of the importance of CTAs. It will describe how the regulatory environment affects them and explain the typical clauses which make up a CTA and what the key differences are between European and the US. By the end of this seminar, you will be confident in spotting and addressing issues that arise when negotiating and drafting clinical trial agreements.

Why should you attend?

  • This seminar will enable you to:
  • Recognise and address the issues that arise when drafting and negotiating clinical trial agreements
  • Gain a better understanding of the legal, contractual and practical issues that affect clinical trial agreements
  • Consider the issues through the differing perspectives of sponsors and health care organisations
  • Complete practical exercises on drafting and negotiating to consolidate your learning

Who Should Attend:

  • Contract managers
  • Clinical contract specialists
  • Clinical trial managers
  • R&D staff
  • Regulatory specialists
  • Lawyers
  • Legal executives


Overview of the legal/policy landscape as it affects the terms of CTAs

  • What is a clinical trial?
  • EU regulatory framework: What are the key regulatory considerations relevant to conducting a clinical trial?
  • Introduction to the parties to the CTA and key roles and responsibilities
  • Policy issues in public hospitals, e.g. UK NHS approval
  • Other ethical/legal issues
  • Standard contracts, e.g. NHS standard CTA
  • Implications of Brexit


Negotiating and drafting CTAs

  • Overview of issues that frequently come up in the negotiation/drafting of CTAs
  • Introduction to case study
  • Discussion of case study
  • Definitions
  • Intellectual property and publication provisions
  • Use of data generated during the trial
  • Data protection, medical records, freedom of information, etc


  • Negotiating and drafting CTAs - Continued discussion of case study:
  • Manufacture of the investigational medicinal product
  • Warranties and indemnities
  • Liabilities and insurance requirements
  • Termination and its consequences

Additional considerations

  • Introduction to differences between US, UK and Continental European legal systems and how they may affect contract drafting
  • Unlicensed product vs off-label use
  • First-in-man studies
  • Investigator-initiated studies
  • Compliance and anti-corruption issues


For more information about this conference visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900